BACKGROUND: Splanchnic vein thrombosis can be the presenting manifestation of myeloproliferative neoplasms. However, the diagnosis of a myeloproliferative neoplasm in these patients is often problematic, and more objective criteria are needed. AIM: To determine the frequency of the mutation JAK2V617F in patients with splanchnic vein thromboses. METHODS: A consecutive series of 108 adult patients with portal vein thrombosis (n = 77) and Budd-Chiari syndrome (n = 31) referred for hemostasis evaluation was retrospectively studied, with a median follow-up of 51 months (1-104). RESULTS: One or more prothrombotic risk factors were present in 63% of the patients. Twenty-four (22%) out of the 108 patients presented the JAK2V617F, including 2 cirrhotic patients. Most had a low mutated allele burden (median 16.5%). JAK2V617F was present in all four patients with a previous diagnosis of a myeloproliferative neoplasm. In nine JAK2V617F-positive patients, the diagnosis of a myeloproliferative neoplasm was made at the thrombosis work-up, during follow-up or after JAK2V617F detection. Among the other 11 patients carrying the mutation, 2 patients have died, 4 had no evidence suggesting a myeloproliferative neoplasm, 1 had a normal bone marrow biopsy, and the other 4 could not be persuaded to undergo a biopsy. Among the patients without an overt myeloproliferative neoplasm, 15 out of 99 (15%) presented the JAK2V617F mutation. None of the JAK2V617F-negative patients have developed signs of a myeloproliferative neoplasm during follow-up. CONCLUSIONS: Our findings suggest that JAK2V617F occurs in a high proportion of patients with splanchnic vein thrombosis, and reinforces the diagnostic utility of JAK2V617F testing in this setting.
BACKGROUND:Splanchnic vein thrombosis can be the presenting manifestation of myeloproliferative neoplasms. However, the diagnosis of a myeloproliferative neoplasm in these patients is often problematic, and more objective criteria are needed. AIM: To determine the frequency of the mutation JAK2V617F in patients with splanchnic vein thromboses. METHODS: A consecutive series of 108 adult patients with portal vein thrombosis (n = 77) and Budd-Chiari syndrome (n = 31) referred for hemostasis evaluation was retrospectively studied, with a median follow-up of 51 months (1-104). RESULTS: One or more prothrombotic risk factors were present in 63% of the patients. Twenty-four (22%) out of the 108 patients presented the JAK2V617F, including 2 cirrhoticpatients. Most had a low mutated allele burden (median 16.5%). JAK2V617F was present in all four patients with a previous diagnosis of a myeloproliferative neoplasm. In nine JAK2V617F-positive patients, the diagnosis of a myeloproliferative neoplasm was made at the thrombosis work-up, during follow-up or after JAK2V617F detection. Among the other 11 patients carrying the mutation, 2 patients have died, 4 had no evidence suggesting a myeloproliferative neoplasm, 1 had a normal bone marrow biopsy, and the other 4 could not be persuaded to undergo a biopsy. Among the patients without an overt myeloproliferative neoplasm, 15 out of 99 (15%) presented the JAK2V617F mutation. None of the JAK2V617F-negative patients have developed signs of a myeloproliferative neoplasm during follow-up. CONCLUSIONS: Our findings suggest that JAK2V617F occurs in a high proportion of patients with splanchnic vein thrombosis, and reinforces the diagnostic utility of JAK2V617F testing in this setting.
Authors: C R Newton; A Graham; L E Heptinstall; S J Powell; C Summers; N Kalsheker; J C Smith; A F Markham Journal: Nucleic Acids Res Date: 1989-04-11 Impact factor: 16.971
Authors: Ross L Levine; Martha Wadleigh; Jan Cools; Benjamin L Ebert; Gerlinde Wernig; Brian J P Huntly; Titus J Boggon; Iwona Wlodarska; Jennifer J Clark; Sandra Moore; Jennifer Adelsperger; Sumin Koo; Jeffrey C Lee; Stacey Gabriel; Thomas Mercher; Alan D'Andrea; Stefan Fröhling; Konstanze Döhner; Peter Marynen; Peter Vandenberghe; Ruben A Mesa; Ayalew Tefferi; James D Griffin; Michael J Eck; William R Sellers; Matthew Meyerson; Todd R Golub; Stephanie J Lee; D Gary Gilliland Journal: Cancer Cell Date: 2005-04 Impact factor: 31.743
Authors: Amy V Jones; Sebastian Kreil; Katerina Zoi; Katherine Waghorn; Claire Curtis; Lingyan Zhang; Joannah Score; Rachel Seear; Andrew J Chase; Francis H Grand; Helen White; Christine Zoi; Dimitris Loukopoulos; Evangelos Terpos; Elisavet-Christine Vervessou; Beate Schultheis; Michael Emig; Thomas Ernst; Eva Lengfelder; Rüdiger Hehlmann; Andreas Hochhaus; David Oscier; Richard T Silver; Andreas Reiter; Nicholas C P Cross Journal: Blood Date: 2005-05-26 Impact factor: 22.113
Authors: Raj K Patel; Nicholas C Lea; Michael A Heneghan; Nigel B Westwood; Dragana Milojkovic; Murugaiyan Thanigaikumar; Deborah Yallop; Roopen Arya; Antonio Pagliuca; Joop Gäken; Julia Wendon; Nigel D Heaton; Ghulam J Mufti Journal: Gastroenterology Date: 2006-06 Impact factor: 22.682
Authors: Animesh Pardanani; Terra L Lasho; Kebede Hussein; Susan M Schwager; Cristy M Finke; Rajiv K Pruthi; Ayalew Tefferi Journal: Mayo Clin Proc Date: 2008-04 Impact factor: 7.616
Authors: Naomi Shin; Young H Kim; Hao Xu; Hai-Bin Shi; Qing-Qiao Zhang; Jean Paul Colon Pons; Ducksoo Kim; Yi Xu; Fei-Yun Wu; Samuel Han; Byung-Boong Lee; Lin-Sun Li Journal: World J Hepatol Date: 2016-06-08
Authors: Francesca R Ponziani; Maria A Zocco; Chiara Campanale; Emanuele Rinninella; Annalisa Tortora; Luca Di Maurizio; Giuseppe Bombardieri; Raimondo De Cristofaro; Anna M De Gaetano; Raffaele Landolfi; Antonio Gasbarrini Journal: World J Gastroenterol Date: 2010-01-14 Impact factor: 5.742
Authors: Markus Peck-Radosavljevic; Bernhard Angermayr; Christian Datz; Arnulf Ferlitsch; Monika Ferlitsch; Valentin Fuhrmann; Michael Häfner; Ludwig Kramer; Andreas Maieron; Berit Payer; Thomas Reiberger; Rudolf Stauber; Rudolf Steininger; Michael Trauner; Siegfried Thurnher; Gregor Ulbrich; Wolfgang Vogel; Heinz Zoller; Ivo Graziadei Journal: Wien Klin Wochenschr Date: 2013-04-12 Impact factor: 1.704
Authors: Jackline P Ayres-Silva; Martin H Bonamino; Maria E Gouveia; Barbara C R Monte-Mor; Diego F Coutinho; Adelmo H Daumas; Cristiana Solza; Esteban Braggio; Ilana Renault Zalcberg Journal: Front Oncol Date: 2018-02-19 Impact factor: 6.244